Results 11 to 20 of about 24,208,296 (151)

Metabolic pathway of the nitrosoureas catalyzed by cytochrome P-450 and NADPH cytochrome P-450 reductase [PDF]

open access: yes
Three highly purified forms of cytochrome P-450 (P-450a, P-450b, P-450c) from Aroclor 1254-induced rat hepatic microsomes catalyzed the monooxygenation of 1-(2- chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea (MeCCNU) and 1-(2-chloroethyl)-3 ...
Potter, David Willard
core   +6 more sources

The Effect of Polymorphisms in the CYP2D6 and CYP2C9 Genes on the Clinical Efficacy of Tramadol and Ketorolac When Using the Accelerated Recovery Protocol in Patients With Uncomplicated Acute Calculous Cholecystitis Who Underwent Cholecystectomy

open access: yesНеотложная медицинская помощь, 2020
Relevance. One of the key components of the accelerated recovery protocols (ARP), in addition to minimizing the surgical approach, is an adequate postoperative analgesia.
A. A. Muradyan   +7 more
doaj   +1 more source

Influence of amino acid residue 374 of cytochrome P-450 2D6 (CYP2D6) on the regio- and enantio-selective metabolism of metoprolol [PDF]

open access: yesBiochemical Journal, 1996
Cytochrome P-450 2D6 (CYP2D6) is an important human drug-metabolizing enzyme responsible for the oxidation of more than 30 widely used therapeutic agents. The enzymes encoded by the published genomic [Kimura, Umeno, Skoda, Meyer and Gonzalez (1989) Am. J. Hum. Genet.
S W, Ellis   +7 more
openaire   +2 more sources

Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection [PDF]

open access: yes, 2008
Autoimmune liver diseases, such as autoimmune hepatitis (AIH) and primary biliary cirrhosis, often have severe consequences for the patient. Because of a lack of appropriate animal models, not much is known about their potential viral etiology. Infection
Hintereder, Gudrun   +23 more
core   +1 more source

The CYP2D6 animal model: how to induce autoimmune hepatitis in mice [PDF]

open access: yes, 2012
Autoimmune hepatitis is a rare but life threatening autoimmune disease of the liver of unknown etiology1,2. In the past many attempts have been made to generate an animal model that reflects the characteristics of the human disease 3-5.
Christen, Urs   +2 more
core   +1 more source

Clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): the influence of gender and genetics (CYP2D6, COMT, 5-HTT). [PDF]

open access: yesPLoS ONE, 2012
The synthetic psychostimulant MDMA (± 3,4-methylenedioxymethamphetamine, ecstasy) acts as an indirect serotonin, dopamine, and norepinephrine agonist and as a mechanism-based inhibitor of the cytochrome P-450 2D6 (CYP2D6).
Ricardo Pardo-Lozano   +10 more
doaj   +1 more source

Citalopram in vitro metabolism in a beagle dog: A role for CYP2D15 in the production of toxic didesmethylcitalopram?

open access: yesVeterinární Medicína, 2023
After administration of the serotonergic antidepressant citalopram (CIT) to beagle dogs, they may experience severe convulsive attacks in relation with considerably higher plasma concentrations of the metabolite didesmethyl-CIT (DDCIT), when compared to ...
B Rochat, E Paus, C Maitre, P Baumann
doaj   +1 more source

Network Pharmacology and Molecular Docking Analysis on Targets and Mechanisms of Berberine in Atypical Antipsychotic-Induced Metabolic Syndrome

open access: yesNatural Product Communications, 2022
Berberine (BBR), an isoquinoline alkaloid, possesses multiply pharmacological effects as a potential therapeutic drug for antipsychotic-induced metabolic syndrome (MetS). However, the underlying therapeutic mechanisms have not been fully elucidated.
Zhuowei Huang, Xiaolan Liu
doaj   +1 more source

Impact of cytochrome P450 2D6 function on the chiral blood plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA) and its phase I and II metabolites in humans [PDF]

open access: yes, 2016
3,4-methylenedioxymethamphetamine (MDMA; ecstasy) metabolism is known to be stereoselective, with preference for S-stereoisomers. Its major metabolic step involves CYP2D6-catalyzed demethylenation to 3,4-dihydroxymethamphetamine (DHMA), followed by ...
Tingelhoff, Eva H.   +26 more
core   +1 more source

Genetic risk factors of cytolysis syndrome in the treatment of recrudescence of chronic cardiovascular diseases

open access: yesРоссийский кардиологический журнал, 2018
Aim. To assess the clinical, biochemical, and genetic risk factors for the development of hepatocyte cytolysis syndrome in patients with a combination of fatty liver disease and recrudescence of chronic cardiovascular pathology.Material and methods.
N. V. Kokh   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy